Gavin Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gavin Wu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Mina S. Makary
Department of Radiology, The Ohio State University Medical Center, Columbus, OH 43210, USA
5 shared publications David S. Shin
Division of Vascular and Interventional Radiology, Department of Radiology, University of Southern California, Los Angeles, USA
3 shared publicationsEric J. Monroe
Section of Vascular and Interventional Radiology, Department of Radiology, University of Wisconsin, Madison, USA
3 shared publicationsJeffrey Forris Beecham Chick
Division of Vascular and Interventional Radiology, Department of Radiology, University of Southern California, Los Angeles, USA
3 shared publicationsMina S. Makary
Division of Vascular and Interventional Radiology, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, USA
3 shared publicationsAnthony N. Hage
Section of Vascular and Interventional Radiology, Department of Radiology, Cooper University Hospital, Camden, USA
2 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (12) , 6358-6368
Prostatic artery embolization and imaging-based biomarkers: current tools in monitoring treatment response and emerging strategies
Prostatic artery embolization (PAE) is a safe and effective minimally invasive treatment for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), including in patients with large prostates, who are poor surgical candidates or wish to avoid the morbidity of conventional surgery or transurethral interventions. As PAE becomes more widely adopted for BPH-related LUTS, objective measures of assessing treatment response are needed beyond symptom-based tools such as the International Prostate Symptom Score (IPSS) and Quality-of-Life (QoL) index. Imaging biomarkers complement these subjective endpoints by quantifying structural, functional, ischemic, and microstructural changes within the prostate before and after embolization. This review summarizes the principal imaging modalities used for biomarker assessment in PAE, with emphasis on ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) scans, and examines the current literature on imaging biomarkers of treatment response. Volumetric biomarkers, including whole prostate volume, central gland volume, and zonal volumetry index, provide quantitative assessment of gland reduction and may help predict clinical improvement, with zonal parameters showing stronger associations with symptomatic outcomes than whole-gland measurements alone. Functional biomarkers such as postvoid residual volume offer objective evaluation of bladder emptying alongside volumetric assessment, whereas ischemia-based biomarkers derived from contrast-enhanced MRI directly reflect embolization-induced devascularization. Diffusion-weighted imaging and apparent diffusion coefficient mapping provide additional information regarding post-embolization tissue remodeling, with b-value selection influencing early infarct detection. Emerging tools, including ultrasound elastography, radiomics, and artificial intelligence-assisted image analysis, may further refine patient selection, standardize response assessment, and improve predictive modeling, though prospective PAE-specific validation remains needed. Imaging biomarkers provide a more objective framework for evaluating PAE treatment response, with the potential to standardize outcome reporting, facilitate earlier identification of treatment success or failure, and guide biomarker-driven clinical decision-making. Prospective validation in larger PAE-specific cohorts remains essential before broader clinical adoption.
- 26 June 2026
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (12) , 6358-6368
Open AccessProstatic artery embolization and imaging-based biomarkers: current tools in monitoring treatment response and emerging strategies
Prostatic artery embolization (PAE) is a safe and effective minimally invasive treatment for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), including in patients with large prostates, who are poor surgical candidates or wish to avoid the morbidity of conventional surgery or transurethral interventions. As PAE becomes more widely adopted for BPH-related LUTS, objective measures of assessing treatment response are needed beyond symptom-based tools such as the International Prostate Symptom Score (IPSS) and Quality-of-Life (QoL) index. Imaging biomarkers complement these subjective endpoints by quantifying structural, functional, ischemic, and microstructural changes within the prostate before and after embolization. This review summarizes the principal imaging modalities used for biomarker assessment in PAE, with emphasis on ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) scans, and examines the current literature on imaging biomarkers of treatment response. Volumetric biomarkers, including whole prostate volume, central gland volume, and zonal volumetry index, provide quantitative assessment of gland reduction and may help predict clinical improvement, with zonal parameters showing stronger associations with symptomatic outcomes than whole-gland measurements alone. Functional biomarkers such as postvoid residual volume offer objective evaluation of bladder emptying alongside volumetric assessment, whereas ischemia-based biomarkers derived from contrast-enhanced MRI directly reflect embolization-induced devascularization. Diffusion-weighted imaging and apparent diffusion coefficient mapping provide additional information regarding post-embolization tissue remodeling, with b-value selection influencing early infarct detection. Emerging tools, including ultrasound elastography, radiomics, and artificial intelligence-assisted image analysis, may further refine patient selection, standardize response assessment, and improve predictive modeling, though prospective PAE-specific validation remains needed. Imaging biomarkers provide a more objective framework for evaluating PAE treatment response, with the potential to standardize outcome reporting, facilitate earlier identification of treatment success or failure, and guide biomarker-driven clinical decision-making. Prospective validation in larger PAE-specific cohorts remains essential before broader clinical adoption.
- Open Access
- 1 May 2026
- Published by Springer Nature in CVIR Endovascular
- Vol. 9 (1) , 49
Adverse event severity in weekend and after-hours interventional radiology: a multi-institutional quality review
Background: Procedures performed after-hours have been associated with worse outcomes in several procedural specialties. Data examining the relationship between procedure timing and adverse event severity in interventional radiology remain limited. This study retrospectively evaluated adverse events reviewed at interventional radiology morbidity and mortality conferences to assess whether procedure timing was associated with differences in adverse event severity and quality-of-care assessment. Results: A total of 547 adverse events occurring across four affiliated hospital sites were included. The cohort comprised 341 males and 206 females with a mean age of 56.2 years. Vascular procedures accounted for 369 events (67.5%), and non-vascular procedures accounted for 178 events (32.5%). Most adverse events occurred during weekday daytime hours ( n = 459, 83.9%), followed by weekday after-hours ( n = 50, 9.1%) and weekend periods ( n = 38, 6.9%). Compared with weekday daytime procedures, a greater proportion of adverse events resulting in death occurred during weekday after-hours and on weekends, as reflected by a higher proportion of Society of Interventional Radiology class F events and Harm Score 9 outcomes ( p < 0.001). In contrast, no significant difference in Quality Control System scores was observed across procedure timing categories ( p = 0.73). Conclusions: Among adverse events reviewed at interventional radiology morbidity and mortality conferences, procedures performed during weekday after-hours and weekend periods were associated with greater adverse event severity, while quality-of-care assessments did not differ by procedure timing. These findings describe patterns within morbidity and mortality-reviewed complications and do not estimate complication rates or population-level risk by procedure timing. The absence of variation in Quality Control System scores supports the hypothesis that observed differences in severity may reflect patient acuity and procedural urgency rather than differences in procedural quality.
- 1 May 2026
- Published by Springer Nature in CVIR Endovascular
- Vol. 9 (1) , 49
Open AccessAdverse event severity in weekend and after-hours interventional radiology: a multi-institutional quality review
Background: Procedures performed after-hours have been associated with worse outcomes in several procedural specialties. Data examining the relationship between procedure timing and adverse event severity in interventional radiology remain limited. This study retrospectively evaluated adverse events reviewed at interventional radiology morbidity and mortality conferences to assess whether procedure timing was associated with differences in adverse event severity and quality-of-care assessment. Results: A total of 547 adverse events occurring across four affiliated hospital sites were included. The cohort comprised 341 males and 206 females with a mean age of 56.2 years. Vascular procedures accounted for 369 events (67.5%), and non-vascular procedures accounted for 178 events (32.5%). Most adverse events occurred during weekday daytime hours ( n = 459, 83.9%), followed by weekday after-hours ( n = 50, 9.1%) and weekend periods ( n = 38, 6.9%). Compared with weekday daytime procedures, a greater proportion of adverse events resulting in death occurred during weekday after-hours and on weekends, as reflected by a higher proportion of Society of Interventional Radiology class F events and Harm Score 9 outcomes ( p < 0.001). In contrast, no significant difference in Quality Control System scores was observed across procedure timing categories ( p = 0.73). Conclusions: Among adverse events reviewed at interventional radiology morbidity and mortality conferences, procedures performed during weekday after-hours and weekend periods were associated with greater adverse event severity, while quality-of-care assessments did not differ by procedure timing. These findings describe patterns within morbidity and mortality-reviewed complications and do not estimate complication rates or population-level risk by procedure timing. The absence of variation in Quality Control System scores supports the hypothesis that observed differences in severity may reflect patient acuity and procedural urgency rather than differences in procedural quality.
- 14 March 2026
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 49 (6) , 1237-1241
Transvenous Embolization for Stomal Variceal Hemorrhage with Versus Without Portal Decompression
- 14 March 2026
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 49 (6) , 1237-1241
Transvenous Embolization for Stomal Variceal Hemorrhage with Versus Without Portal Decompression
- Open Access
- 28 October 2025
- Published by Springer Nature in CVIR Endovascular
- Vol. 8 (1) , 1-4
Underreporting of inferior vena cava filter characteristics in diagnostic radiology reports: a call for standardization
- 28 October 2025
- Published by Springer Nature in CVIR Endovascular
- Vol. 8 (1) , 1-4
Open AccessUnderreporting of inferior vena cava filter characteristics in diagnostic radiology reports: a call for standardization
- Open Access
- 23 August 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (4) , 2148-2152
Large-bore aspiration of complex intra-abdominal abscesses using a mechanical aspiration device
Purpose: To describe the use of a large-bore mechanical aspiration system (FlowTriever Aspiration Catheter) as an off-label intervention for the evacuation of complex intra-abdominal abscesses that were refractory to standard percutaneous drainage techniques. Methods: Two patients with large, complex intra-abdominal abscesses underwent aspiration using the FlowTriever Aspiration Catheter following failure of conventional catheter drainage. One patient had a walled-off necrotic collection from necrotizing pancreatitis; the other developed a postoperative abscess following appendectomy for perforated appendicitis. In each case, tract dilation was performed to accommodate the large-bore aspiration catheter, and follow-up CT imaging was used to assess treatment response. Results: In both cases, the FlowTriever Aspiration Catheter enabled high-flow aspiration of solid and purulent material, with successful placement of large-bore drainage catheters. Follow-up imaging demonstrated marked reduction or near-complete collapse of the abscess cavities. No procedure-related complications were observed. Conclusion: Large-bore mechanical aspiration with the FlowTriever Aspiration Catheter may offer an effective adjunct or alternative to catheter upsizing and fibrinolytic therapy in patients with complex intra-abdominal abscesses, particularly when standard drainage techniques are unsuccessful. This approach may reduce the need for repeat interventions or surgical debridement in appropriately selected patients.
- 23 August 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (4) , 2148-2152
Open AccessLarge-bore aspiration of complex intra-abdominal abscesses using a mechanical aspiration device
Purpose: To describe the use of a large-bore mechanical aspiration system (FlowTriever Aspiration Catheter) as an off-label intervention for the evacuation of complex intra-abdominal abscesses that were refractory to standard percutaneous drainage techniques. Methods: Two patients with large, complex intra-abdominal abscesses underwent aspiration using the FlowTriever Aspiration Catheter following failure of conventional catheter drainage. One patient had a walled-off necrotic collection from necrotizing pancreatitis; the other developed a postoperative abscess following appendectomy for perforated appendicitis. In each case, tract dilation was performed to accommodate the large-bore aspiration catheter, and follow-up CT imaging was used to assess treatment response. Results: In both cases, the FlowTriever Aspiration Catheter enabled high-flow aspiration of solid and purulent material, with successful placement of large-bore drainage catheters. Follow-up imaging demonstrated marked reduction or near-complete collapse of the abscess cavities. No procedure-related complications were observed. Conclusion: Large-bore mechanical aspiration with the FlowTriever Aspiration Catheter may offer an effective adjunct or alternative to catheter upsizing and fibrinolytic therapy in patients with complex intra-abdominal abscesses, particularly when standard drainage techniques are unsuccessful. This approach may reduce the need for repeat interventions or surgical debridement in appropriately selected patients.
- Open Access
- 11 June 2025
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 28 (3) , 101597
Effect of Radiation Therapy on CT Attenuation of Bone in Patients with Anorectal Cancer Treated with Chemotherapy
- 11 June 2025
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 28 (3) , 101597
Open AccessEffect of Radiation Therapy on CT Attenuation of Bone in Patients with Anorectal Cancer Treated with Chemotherapy
- Open Access
Expanding the Scope of Interventional Oncology: Locoregional Therapies in Extrahepatic Malignancies
Background/Objectives: Locoregional therapies (LRTs), including transarterial embolization (TAE), transarterial chemoembolization (TACE), and transarterial radioembolization (TARE), have become integral in the management of hepatocellular carcinoma (HCC) in recent decades and continue to shape evolving treatment strategies. While their role in liver tumor management is well established, their potential for treating extrahepatic malignancies is gaining increasing attention. Notably, growing research has highlighted the promising applications of TAE, TACE, and TARE in extrahepatic cancers such as glioblastoma (GBM), soft tissue sarcomas (STSs), prostate cancer (PCa), pancreatic cancer, and renal cell carcinoma (RCC). This review aims to explore these novel applications, providing a comprehensive summary of the current literature, examining clinical outcomes, and discussing future directions for integrating these techniques into broader oncologic treatment strategies. Methods: A systematic literature review was conducted focusing on LRTs such as TAE, TACE, and TARE in extrahepatic malignancies. Studies published between May 1998 and December 2024 were included, emphasizing outcomes in GBM, STS, PCa, pancreatic cancer, and RCC. Data extraction prioritized clinical outcomes, safety profiles, and procedural efficacy. Results: LRTs demonstrated significant potential in managing extrahepatic malignancies, with TAE, TACE, and TARE showing promising results in palliative management and tumor control. Across studies, these therapies exhibited varying degrees of success in improving progression-free survival and overall survival, with minimal systemic toxicity. Conclusions: The expanding application of LRTs in extrahepatic malignancies highlights their transformative potential in interventional oncology. By offering targeted, minimally invasive treatment options, these modalities bridge critical gaps in managing tumors refractory to conventional therapies. Future research should focus on standardizing protocols, optimizing patient selection, and exploring combination therapies to maximize their clinical efficacy.
Open AccessExpanding the Scope of Interventional Oncology: Locoregional Therapies in Extrahepatic Malignancies
Background/Objectives: Locoregional therapies (LRTs), including transarterial embolization (TAE), transarterial chemoembolization (TACE), and transarterial radioembolization (TARE), have become integral in the management of hepatocellular carcinoma (HCC) in recent decades and continue to shape evolving treatment strategies. While their role in liver tumor management is well established, their potential for treating extrahepatic malignancies is gaining increasing attention. Notably, growing research has highlighted the promising applications of TAE, TACE, and TARE in extrahepatic cancers such as glioblastoma (GBM), soft tissue sarcomas (STSs), prostate cancer (PCa), pancreatic cancer, and renal cell carcinoma (RCC). This review aims to explore these novel applications, providing a comprehensive summary of the current literature, examining clinical outcomes, and discussing future directions for integrating these techniques into broader oncologic treatment strategies. Methods: A systematic literature review was conducted focusing on LRTs such as TAE, TACE, and TARE in extrahepatic malignancies. Studies published between May 1998 and December 2024 were included, emphasizing outcomes in GBM, STS, PCa, pancreatic cancer, and RCC. Data extraction prioritized clinical outcomes, safety profiles, and procedural efficacy. Results: LRTs demonstrated significant potential in managing extrahepatic malignancies, with TAE, TACE, and TARE showing promising results in palliative management and tumor control. Across studies, these therapies exhibited varying degrees of success in improving progression-free survival and overall survival, with minimal systemic toxicity. Conclusions: The expanding application of LRTs in extrahepatic malignancies highlights their transformative potential in interventional oncology. By offering targeted, minimally invasive treatment options, these modalities bridge critical gaps in managing tumors refractory to conventional therapies. Future research should focus on standardizing protocols, optimizing patient selection, and exploring combination therapies to maximize their clinical efficacy.
- Open Access
Hepatocellular Carcinoma Surveillance Strategies: Major Guidelines and Screening Advances
Background/Objectives: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with prognosis and treatment outcomes that are significantly influenced by the stage at diagnosis. Early detection through regular surveillance is crucial for improving patient outcomes, especially in high-risk groups such as those with cirrhosis or chronic hepatitis B. Geographic variations in HCC risk factors, including viral hepatitis and non-alcoholic fatty liver disease (NAFLD), have led to the development of different international surveillance guidelines. This review aims to compare and evaluate the surveillance strategies proposed by the Asian Pacific Association for the Study of the Liver (APASL), the American Association for the Study of Liver Diseases (AASLD), and the European Association for the Study of the Liver and European Organization for Research and Treatment of Cancer (EASL–EORTC). Methods: The review examined and compared major international guidelines on HCC surveillance, focusing on patient selection, imaging modalities, and the integration of biomarkers. We also explored recent advancements in screening techniques, including artificial intelligence and emerging biomarkers, to identify future directions for improving surveillance strategies. Results: Our analysis identified key differences in the guidelines, particularly in imaging modality preferences and the use of biomarkers for early detection. While all guidelines place emphasis on high-risk populations, the inclusion criteria and surveillance intervals vary. Additionally, novel technologies such as artificial intelligence show potential to enhance the accuracy and efficiency of HCC detection. Conclusions: This review highlights the need to harmonize the international guidelines, particularly in regard to patients with non-cirrhotic NAFLD who remain under-represented in current surveillance protocols. Future research should focus on integrating emerging technologies and biomarkers to improve early detection and overall patient outcomes.
Open AccessHepatocellular Carcinoma Surveillance Strategies: Major Guidelines and Screening Advances
Background/Objectives: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with prognosis and treatment outcomes that are significantly influenced by the stage at diagnosis. Early detection through regular surveillance is crucial for improving patient outcomes, especially in high-risk groups such as those with cirrhosis or chronic hepatitis B. Geographic variations in HCC risk factors, including viral hepatitis and non-alcoholic fatty liver disease (NAFLD), have led to the development of different international surveillance guidelines. This review aims to compare and evaluate the surveillance strategies proposed by the Asian Pacific Association for the Study of the Liver (APASL), the American Association for the Study of Liver Diseases (AASLD), and the European Association for the Study of the Liver and European Organization for Research and Treatment of Cancer (EASL–EORTC). Methods: The review examined and compared major international guidelines on HCC surveillance, focusing on patient selection, imaging modalities, and the integration of biomarkers. We also explored recent advancements in screening techniques, including artificial intelligence and emerging biomarkers, to identify future directions for improving surveillance strategies. Results: Our analysis identified key differences in the guidelines, particularly in imaging modality preferences and the use of biomarkers for early detection. While all guidelines place emphasis on high-risk populations, the inclusion criteria and surveillance intervals vary. Additionally, novel technologies such as artificial intelligence show potential to enhance the accuracy and efficiency of HCC detection. Conclusions: This review highlights the need to harmonize the international guidelines, particularly in regard to patients with non-cirrhotic NAFLD who remain under-represented in current surveillance protocols. Future research should focus on integrating emerging technologies and biomarkers to improve early detection and overall patient outcomes.
- Open Access
- 27 June 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (7) , 1432
Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma
More than 800,000 people worldwide are diagnosed with HCC (hepatocellular carcinoma) each year, with approximately 700,000 deaths alone occurring in that same year. Treatment of HCC presents complex therapeutic challenges, particularly in intermediate and advanced stages. LRTs such as transarterial chemoembolization (TACE) and ablations have been the mainstay treatment for early to intermediate-stage HCC, and systemic therapies are used to treat intermediate-late-stage HCC. However, novel literature describing combining LRT with systemic therapies has shown promising results. This review explores recent advances in both liver-directed techniques for hepatocellular carcinoma, including bland transarterial embolization, chemoembolization, radioembolization, and ablative therapies in conjunction as well as with systemic therapies, with a focus on combination therapies, patient selection, procedural technique, periprocedural management, and outcomes. Our findings suggest that LRT combined with systemic therapies is a viable strategy for improving progression-free survival and time to progression for patients with intermediate-to-late-stage HCC. However, further investigation is required to refine treatment protocols and define patient cohorts that would benefit the most.
- 27 June 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (7) , 1432
Open AccessExamining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma
More than 800,000 people worldwide are diagnosed with HCC (hepatocellular carcinoma) each year, with approximately 700,000 deaths alone occurring in that same year. Treatment of HCC presents complex therapeutic challenges, particularly in intermediate and advanced stages. LRTs such as transarterial chemoembolization (TACE) and ablations have been the mainstay treatment for early to intermediate-stage HCC, and systemic therapies are used to treat intermediate-late-stage HCC. However, novel literature describing combining LRT with systemic therapies has shown promising results. This review explores recent advances in both liver-directed techniques for hepatocellular carcinoma, including bland transarterial embolization, chemoembolization, radioembolization, and ablative therapies in conjunction as well as with systemic therapies, with a focus on combination therapies, patient selection, procedural technique, periprocedural management, and outcomes. Our findings suggest that LRT combined with systemic therapies is a viable strategy for improving progression-free survival and time to progression for patients with intermediate-to-late-stage HCC. However, further investigation is required to refine treatment protocols and define patient cohorts that would benefit the most.